Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

计划入组 116 人 · 首次发布于 2014 年 1 月 17 日

Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases

计划入组 810 人 · 首次发布于 2026 年 3 月 20 日

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

计划入组 138 人 · 首次发布于 2013 年 2 月 5 日

XER-T10

AER-601

AER-005

Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie

Netherlands

Per Humpert

Germany

Klinikum Rechts der Isar der Technischen Universität München

Germany

CheckMate-9ER: Glycoproteomic Analysis Identifies Potential Biomarkers for Nivolumab Plus Cabozantinib in Advanced RCC

Cabozantinib/Nivolumab Shows Consistent Benefits in RCC, Except for Favorable-Risk Group

IO/TKI Doublets Show Consistent Efficacy in Metastatic Clear Cell Renal Cell Carcinoma